New York, NY USA

Our News on Newswise

Immunotherapy Combo Increases Progression-Free Survival in Advanced Melanoma Patients

Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab and ipilimumab or nivolumab alone significantly increases progression-free survival over using ipilimumab alone, according to Memorial Sloan Kettering...
31-May-2015 7:30 AM EDT

Memorial Sloan Kettering Cancer Center Receives Record Gift of $150 Million from David Koch for Innovative Patient Care Facility

Memorial Sloan Kettering Cancer Center (MSK) announced that it has received the largest gift in its history, a commitment of $150 million from long-time MSK board member David H. Koch. This unprecedented contribution will transform cancer care with...
20-May-2015 8:05 AM EDT

Memorial Sloan Kettering Cancer Center “Specializes in You” with an Innovative and Personalized Digital Landscape

Memorial Sloan Kettering Cancer Center (MSK) introduced a new, consumer-friendly web presence for www.mskcc.org (Memorial Sloan Kettering Cancer Center) and www.sloankettering.edu (Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences,...
5-May-2015 2:15 PM EDT

Memorial Sloan Kettering Opens First Pediatric CAR T Cell Clinical Trial

Researchers from Memorial Sloan Kettering Cancer Center (MSK) are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising...
10-Apr-2015 9:05 AM EDT

Memorial Sloan Kettering Debuts New Mobile Application for Patients

Memorial Sloan Kettering Cancer Center (MSK) has debuted MyMSK, a new mobile application. The app, compatible with iPad, iPhone, and all iOS devices, allows MSK patients to quickly and easily access their lab and radiology results, view their...
23-Feb-2015 4:00 PM EST

NIH Awards Seven-Year Grant to Weill Cornell Medical College to Tackle Global Tuberculosis Epidemic

In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health has awarded Weill Cornell Medical College more than $6.2 million in first-year funding to support a research collaboration...
19-Feb-2015 11:00 AM EST

Memorial Sloan Kettering Study Shows New Kind of Targeted Drug Has Promise for Leukemia Patients

A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial.
7-Dec-2014 12:30 PM EST

Studies Led by Memorial Sloan Kettering Investigators Show Immunotherapy Drugs Improve Outcomes in Hodgkin Lymphoma Patients

In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. For Classical Hodgkin lymphoma patients, two phase I studies are already...
6-Dec-2014 1:00 PM EST

Our YouTube Videos